Claims
- 1. A compound of the structure
- 2. A compound of claim 1 wherein R1 is Me.
- 3. A compound of claim 2 wherein Y is a bond.
- 4. A compound of claim 3 wherein X is S.
- 5. A compound of claim 3 wherein X is O.
- 6. A compound of claim 4 selected from the group consisting of
- 7. A compound of Claim 5 selected from the group consisting of
- 8. A compound of claim 1 selected from the group consisting of
- 9. A compound of claim 1 selected from the group consisting of
- 10. A compound of claim 1 wherein Y is O.
- 11. A compound of claim 10 wherein X is S.
- 12. A compound of claim 10 wherein X is O.
- 13. A compound of claim 11 selected from the group consisting of
- 14. A compound of claim 12 selected from the group consisting of
- 15. A compound of claim 1 selected from the group consisting of
- 16. A compound of claim 1 selected from the group consisting of
- 17. A composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier.
- 18. The composition of claim 17 wherein the compound of claim 1 is selected from the group consisting of
- 19. A method for treatment of a disease or condition characterized by undesired cellular hyperproliferation comprising administering to a subject in need of treatment a therapeutically effective dose of a composition of claim 19.
- 20. The method of claim 19 wherein the disease or condition characterized by undesired cellular hyperproliferation is cancer.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. §119(e) to U.S. provisional patent application serial No. 60/333,465, filed Nov. 26, 2001, which is incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60333465 |
Nov 2001 |
US |